GlassScriptPhysician profile
Michael D Franklin
NPI 1881618577
$3,160.56
in general payments reported to CMS, 2019-2025
35 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $412 · 2021: $308 · 2022: $514 · 2023: $601 · 2024: $438 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,684.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $535.73 | 2020-2025 | Inspire |
| Glaxosmithkline, LLC. | $468.32 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $259.46 | 2019-2025 | |
| Aerin Medical INC. | $247.13 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.15 | 2019-2025 | Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $220.41 | 2019-2024 | Dupixent |
| Acclarent, INC | $169.34 | 2019-2023 | Relieva Tract, Acclarent Aera, Trudi Nav Cable |
| Intersect Ent, INC. | $148.29 | 2019-2022 | |
| Optinose US, INC. | $142.23 | 2019-2024 | |
| Xoran Technologies LLC | $82.36 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $71.10 | 2025 | |
| Novartis Pharmaceuticals Corporation | $69.80 | 2022-2025 | |
| Smith+Nephew, INC. | $42.31 | 2025 | Halo, Tula, Rf20000 |
| Merck Sharp & Dohme LLC | $37.77 | 2023-2025 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.99 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $35.43 | 2019 | |
| Integra Lifesciences Corporation | $34.41 | 2024-2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Takeda Pharmaceuticals U.S.A., INC. | $32.20 | 2023-2025 | Eohilia, Takhzyro |
| Phathom Pharmaceuticals, INC. | $28.69 | 2024 | Voquezna |
| Amgen INC. | $27.52 | 2019-2021 | |
| Genentech USA, INC. | $22.14 | 2023 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $21.00 | 2025 | Neffy |
| Depuy Synthes Sales INC. | $20.63 | 2022 | |
| Greer Laboratories, INC. | $19.82 | 2023 | Oralair |
| Cochlear Americas | $19.44 | 2025 | Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant |
| Aesculap, INC. | $16.89 | 2023 | Elan 4 |
| Hologic Sales and Service, LLC | $16.83 | 2023 | Coolseal Generator |
| Ambu INC. | $15.29 | 2024 | |
| Hikma Pharmaceuticals USA | $14.54 | 2023 | Ryaltris |
| Kaleo, INC. | $13.97 | 2022 | |
| Eisai INC. | $13.95 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.76 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.71 | 2021 | |
| Medtronic USA, INC. | $12.51 | 2019 | |
| Sanofi Pasteur INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.